Dr. Richard Stratford and Dr. Trevor Clancy are the founders of NEC OncoImmunity AS, a company that has developed artificial intelligence technologies against cancer, which will now also be used for a SARS-COV-2 vaccine.

Artificial intelligence in the fight against COVID-19

Dr. Richard Stratford and Dr. Trevor Clancy, founders of OncoImmunity

Our member NEC OncoImmunity has adapted their cancer-fighting artificial intelligence technology to combat COVID-19.

Advanced cancer technologies and artificial intelligence may prove to be key in the search for a vaccine against the SARS-COV-2 virus. The Norwegian biotech company NEC OncoImmunity AS (NOI) is now accelerating efforts to create a vaccine to combat the COVID-19 pandemic.

“This COVID-19 project represents an exciting opportunity for NOI to showcase its AI-driven epitope prediction platform the “NEC Immune Profiler” in the field of infectious disease. Whilst NOI has focused its efforts to-date on the oncology field, especially the design of personalized therapeutic cancer vaccines, its AL-platform is equally well suited to designing vaccines to address infectious diseases,” said Dr. Richard Stratford, Chief Executive Officer, at NEC OncoImmunity.

This week, NEC OncoImmunity AS announced analysis results from efforts using AI prediction platforms to design blueprints for SARS-CoV-2 vaccines that can drive potent T-cell responses in the majority of the global population.

These AI prediction platforms are based on the AI technology used by NEC and NOI in the development of personalized neoantigen cancer vaccines.

“It is encouraging that our AI and bioinformatics platform can design vaccine blueprints that have the potential to induce a broad T-cell response, that may not only be protective, but also stimulate a long-lived memory immune responses against SARS-CoV-2 and its future mutated versions”, said Dr. Trevor Clancy, Chief Scientific Officer, at NEC OncoImmunity and the lead corresponding author in the paper.

Artificial intelligence against cancer

NEC OncoImmunity is a Norwegian biotech company, founded by Dr. Richard Stratford and Dr. Trevor Clancy in 2014 and the company has been a member of Oslo Cancer Cluster since its early days.

The founders’ vision was to use innovative software solutions for the development of personalized neoantigen vaccines. The machine learning software they have developed can identify neoantigens, which are key to unlocking the immune system and combating cancer.

NEC OncoImmunity developed the technology and grew the company in the Oslo Cancer Cluster ecosystem, making use of the cluster’s advice and support, and networking and partnering opportunities.

Backed by a tech corporation

In 2019, the Japanese multinational tech corporation NEC acquired OncoImmunity AS. NEC had recently launched an artificial intelligence driven drug discovery business and stated that NEC OncoImmunity AS would be integral in developing NEC’s immunotherapy pipeline.

NEC OncoImmunity have been working hard for the last months to adapt their technologies to help in the fight against COVID-19.

“As a company that seeks to enhance the well-being of society, NEC will continue to capitalize on research and development that maximizes the strengths of our AI technology to help prevent the spread of COVID-19. In collaboration with companies and institutions around the world, we aim to enable people to live their daily lives with as much safety and security as possible,” said Motoo Nishihara, Executive Vice President and Chief Technology Officer at NEC.

NEC is now publishing this research to support scientific advancements in the field and is ready to start partnering efforts to pursue the development of an effective vaccine targeting the global population.

 

Sign up to our monthly newsletter

Bjørn Klem, general manager, and Janne Nestvold, laboratory manager, are excited to continue developing Oslo Cancer Cluster Incubator and its infrastructure for cell therapy research.

Accelerating cell therapies against cancer

Björn Klem and Janne Nestvold celebrate that the Oslo Cancer Cluster Incubator has been nominated among Europe's 20 best incubators.

Oslo Cancer Cluster Incubator has received a grant from the City of Oslo, which will be used to develop the infrastructure for cancer cell therapies.

Oslo Cancer Cluster Incubator has received NOK 300 000 in 2020 from the City of Oslo for a project that will support the development of a type of cancer treatment, known as cell therapies (scroll down to the bottom of this page to read a definition for cell therapy). Different forms of cancer cellular therapies are being explored in the Incubator, including genetically modified immune cells.

Cell therapies have the potential to cure cancer and turn it into a chronic disease. More research is however needed to document the full potential of cell therapies.

Specialised cell laboratory facility

The project involves setting up a specialised facility, which will be used for pre-clinical research and development of cell-based medicinal products.

Oslo Cancer Cluster Incubator’s laboratories are currently used for the design of therapeutic cells and to assess the effectiveness and safety of these cells in pre-clinical testing.

The funding from the City of Oslo will enable Oslo Cancer Cluster Incubator to expand the laboratories with the appropriate infrastructure and equipment. The laboratories will support researchers and companies in their development of new cell-based therapies. The initiative is hopefully a first step to establish production of T cell therapies in Norway as part of building a viable health industry.

Janne Nestvold, laboratory manager at Oslo Cancer Cluster Incubator, will coordinate the project.

“The specialised facility enables the Incubator to contribute in the development of cancer cell-based therapies in a preclinical setting,” said Janne Nestvold.

Several research groups in the Incubator already focus on the development of cell therapies. Now, they will have access to dedicated spaces with much needed equipment.

Supporting public-private research collaboration

Oslo Cancer Cluster Incubator is located next to the Norwegian Radium Hospital, one of Europe’s leading cancer hospitals and a part of Oslo University Hospital.

The Incubator’s partnership with Oslo University Hospital is one-of-a-kind in Norway. Hospital research staff work side-by-side with researchers from private companies and exchange experiences in a collaborative setting. They are also connected, through Oslo Cancer Cluster, to a global network of key players in the cancer research field.

Bjørn Klem, general manager of Oslo Cancer Cluster Incubator, hopes the Incubator can further assist both hospital research staff and researchers from private companies to bring forward new treatments.

“The support from City of Oslo is much appreciated as it enables us to take this important field of cell therapy forward, by supporting commercialisation of the growing number of start-ups in this area. This will allow companies to grow in Norway and create jobs, supporting the vision of the Oslo Science City initiative,” said Bjørn Klem.

About the RIP funding

The regional innovation programme (RIP) for the Oslo region has funded a total of NOK 25 million for business development and innovation in 2020.

The goal of RIP is to strengthen the Oslo region’s international competitiveness in cluster- and network development, entrepreneurship, supplier development and commercialisation.

This year’s award had a special emphasis on the health sector, marked by the ongoing coronavirus pandemic. More than ever, it has become important to support the local innovation clusters and the Norwegian health start-up companies.

 

DEFINITION

CAR T-cell therapy is a type of treatment in which a patient’s T cells (a type of immune system cell) are changed in the laboratory so they more effectively will attack cancer cells. T cells are a specific type of white blood cells taken from a patient’s blood. Then the gene coding for a receptor that binds to a protein on the patient’s cancer cells, is added to the T cell in the laboratory. The receptor is called a chimeric antigen receptor (CAR) and enable the patient immune system to better recognise and fight cancer cells. Large numbers of the CAR T cells are then grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is approved for treatment of some cancer patients (leukaemia or lymfoma) and is studied in the treatment of many other types of cancer with promising effects.
Source: National Cancer Institute

 

Click here to sign up for Oslo Cancer Cluster Newsletter

Computers with different software and programming language is necessary to learn about machine learning and artificial intelligence. PhD student Øyvind Sigmundsson Skøyen explains to Jakob, August, Magnus and Jørgen how to program the game Snake so that the snake always survives.

Programming to understand artificial intelligence

Students learning Artificial Intelligence, Machine Learning and Neural Networks

This article was originally published in Norwegian on our School Collaboration website.

How can programming, artificial intelligence and machine learning help us understand the human brain?

Four students from Ullern Upper Secondary School spent two days in the beginning of March on a placement in the Department of Physics at the University of Oslo. Jakob, August, Jørgen and Magnus learned how to program the snake in the game Snake to survive. At the same time, they learned about artificial intelligence, neural networks and machine learning.

Every spring, Professors Anders Malthe-Sørenssen and Marianne Fyhn at the University of Oslo receive eight students from Ullern Upper Secondary School on a placement.

Marianne Fyhn’s research group consists of some of the leading neuroscientists in the world. The four biology students Chiara, Eline, Tora and Eilin from Ullern Upper Secondary School spent the placement training rats and learned how research on rats can provide valuable knowledge about the human brain.

Anders Malthe-Sørenssen is the Director of CCSE (the Center for Computing in Science Education), where the students Magnus Trandokken, August Natvik, Jørgen Hamsund and Jakob Weidel were on another placement.

“There are three PhD students here, who are teaching the Ullern students. At the end of the day, they will gain a better understanding of what artificial intelligence is. We wish to explain the concept to them and give them an insight into what machine learning, neural networks and programming are,” said Malthe-Sørenssen.

  • Scroll to the bottom of this page to read the definitions for machine learning, neural networks and artificial intelligence.

Malthe-Sørenssen and the PhD students tested a new teaching tool on the Ullern students. If it is successful, more students will be able to access it to learn about artificial intelligence. Malthe-Sørenssen and his research group also try to improve the teaching of advanced mathematics, physics and programming in upper secondary schools.

Students learning artificial intelligence, machine learning and neural networks

Øyvind Sigmundsson Skøyen (in the middle) was one of the PhD students that taught the students from Ullern Upper Secondary School. Here, he is helping Jakob Weidel, who is in his first year. To the right is August Natvik, who is graduating this year. Photo: Elisabeth Kirkeng Andersen

Making the snake immortal

Jakob, Magnus, August and Jørgen programmed the game Snake in the programming language Python. This is a programming language that is available for free, an “open source”. You can download it here.

The point of the game Snake is to keep a snake alive for as long as possible. It lives in a square, where it eats candy so that its tail grows. The purpose of the game is to make sure the snake doesn’t crash into itself while it is growing because if it crashes, the snake dies. But it is not that easy. Try it yourself here.

“The students will program the snake so that it can learn where it is smart to move to eat the candy, while at the same time avoiding to crash into its growing tail. It is a good way to understand a little artificial intelligence and machine learning,” said Malthe-Sørenssen.

The three PhD students Sebastian Winther-Larsen, Øyvind Sigmundsson Skøyen and Even Marius Nordhagen were there to teach the Ullern students.

Øyvind had just finished showing the students how to programme the snake when it was Even’s turn to teach.

“What du you already know about machine learning?” Even asked.

“I have seen a little bit on YouTube,” Jakob replied.

“I know the theory, but I haven’t tried it myself,” Magnus said.

Even explained that he would present the theories behind machine learning and neural networks first, and then let the students create a neural network for Snake.

“Linear regression – a theory we often use in mathematics – is a simple form of machine learning. It is about producing a function that gives us the best line between two points. We use something called the method of least squares,” Even said.

Ullern students learning artificial intelligence, machine learning and neural networks.

Espen Marius Nordhagen (to the right) explains to the students from Ullern that regression is a simple form of machine learning. August Natvik is following closely. Photo: Elisabeth Kirkeng Andersen

Even explained that machine learning is used in image analysis. A computer can be taught to recognise and see the difference between several objects in a picture. The objects can be cars, bikes, humans, or other things. The computer can then be taught to create the images, which are then called generative models. Voice recognition, such as the virtual assistant Siri for iPhone users, is also based on machine learning, just like self-driving cars and buses.

“In order to understand artificial intelligence, you have to know what a neural network is. The concept is inspired by biology, neuroscience, and how human beings learn and remember. A neural network is a simplification of the human brain. The brain is in reality much more complicated,” Even explained.

“What is actually the difference between machine learning and artificial intelligence?” Jørgen asked.

Even explained that regression is machine learning, but not artificial intelligence.

“If you have a neural network with several layers, a so-called ‘deep neural network’, it is artificial intelligence. Then you will observe that something is happening with the data you receive from the neural network, it will be something you do not understand and cannot model, but it is consistent with reality,” Even said.

Learned new subjects

Magnus, August and Jørgen are all in the third year and have specialised in the natural sciences, with different combinations of mathematics, physics, technology, research, programming and computer modelling.

After graduating, all three of them will go to military school. Afterwards, Jørgen and Magnus are tempted to study at NTNU.

“The Industrial Economics programme at NTNU seems really good. Maybe I will combine it with the Entrepreneurship Programme, which is also at NTNU. Then I can start my own company after I finished studying. I am also thinking about a career in the military,” said Magnus.

The Ullern students agreed that the placement at the Department of Physics had been difficult, but fun and educational too.

“They are really good at teaching here. It has been difficult, because we haven’t studied these subjects before and everything new is always difficult,” said Jørgen.

Jakob Weidel is still in his first year and is thinking about studying the same subjects as the other three Ullern students. He was asked to participate in the placement after he helped Tom Werner Halvårsrød, the IT administrator at Ullern Upper Secondary School, to programme Excel sheets, which are used in the school.

“I have made a few apps and developed a few websites and used different types of programming languages. I have never used Python before, so it has been fun to learn something new,” said Jakob.

(image caption) Anders Malthe-Sørenssen is a professor at CCSE (the Centre for Computing in Science Education) at the University of Oslo. He and his research group are active in many different areas of research, including improving how physics is taught and understanding how the brain works through advanced mathematical models. Photo: Elisabeth Kirkeng Andersen.

Anders Malthe-Sørenssen is a professor at CCSE (the Centre for Computing in Science Education) at the University of Oslo. He and his research group are active in many different areas of research, including improving how physics is taught and understanding how the brain works through advanced mathematical models. Photo: Elisabeth Kirkeng Andersen

Neural networks and neuroscience

Malthe-Sørenssen’s and Fyhn’s research groups collaborate in a field of biology and physics, which is about research into how the human brain works and neural networks, in the projects DigiBrain and CINPLA. CINPLA is an acronym for Centre for Integrative Neuroplasticity.

“Here at the Department of Physics, we create computer models of neural networks. Then, we compare our models with Marianne’s discoveries about how the brain works from her studies on rats and mice. So far, we have seen that our models give a good picture of what is actually happening in the brain, but we are far from finished,” says Malthe-Sørenssen.

His popular research group receives over 1 000 job applications every year, but they want to keep prioritising student placements.

“We are dedicated to contributing to improving the programming skills in schools. One of our employees has developed the new subject and the syllabus for programming and computer modelling, which will be implemented in upper secondary schools by autumn 2020. Programming will then be used to teach several subjects, including mathematics,” Malthe-Sørenssen says.

He thinks it is good to contribute to raising the level of skills in the local schools around the Department of Physics at the University of Oslo.

What is a placement?

Oslo Cancer Cluster and Ullern Upper Secondary School have an active school collaboration project. The collaboration gives students at the school the opportunity to take part in work placements at different companies and research groups at Oslo University Hospital, at the University of Oslo and with members of Oslo Cancer Cluster.

On the placements, the students get to learn about different subject areas directly from experts and they get the opportunity to do practical laboratory work. The purpose of the placements is to give the students an insight into the practical everyday life of different professions and what career opportunities that different academic degrees hold.

DEFINITIONS

Neural Networks: A neural network is a group term for data structures, and their algorithms, that has been inspired by the way nerve cells in the brain are organised. Neural networks are among the key concepts in machine learning and artificial intelligence.

Machine learning: Machine learning is a special area within artificial intelligence, where you use statistical models to help computers to find patterns in large data quantities. The machine “learns” instead of being programmed.

Artificial intelligence: Artificial intelligence is information technology that adapts its own activity and therefore seems intelligent. A computer that is able to solve assignments without instructions from a human on how to do it, has artificial intelligence.

Sign up to our monthly newsletter

 

New member: Glaxo Smith Kline

Image of Oslo Cancer Cluster Innovation Park

In this article series, we will introduce the new members of our oncology cluster.

Find out how Glaxo Smith Kline (GSK), the latest global pharmaceutical company to enter into our ecosystem, is contributing to the oncology field.

Glaxo Smith Kline is one of the largest research-based pharmaceutical companies in the world, with over 80 employees located in Norway. The company was founded in 2001, but its history can be traced all the way back to the 1700s. Today, they have an impressive portfolio of vaccines, as well as many promising immunotherapy treatments underway.

We asked a couple of questions to Halvard Grønlien, country medical director of GSK Norway, to find out more about their plans in the oncology area.

Tell us about GSK and how the company is involved in the cancer field.

“GSK is a science-led global healthcare company with more than 100 000 employees in over 150 countries and around 80 people in GSK Norway. Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies. Our pharmaceutical and vaccines businesses have a broad portfolio of innovative and established vaccines and medicines with commercial leadership in respiratory and HIV. Our vaccines business has a portfolio of more than 30 vaccines, helping to protect people against 21 diseases. We are the biggest supplier of vaccines to the Norwegian immunization program. Our R&D approach focuses on science related to the immune system, use of genetics and advanced technologies, and our strategy is to bring differentiated, high-quality and needed healthcare products to as many people as possible.

“Within oncology, we are committed to maximizing patient survival through the development of transformational medicines. Since 2018, we have more than doubled the number of oncology assets in clinical development through our own science, the acquisition of TESARO and other alliances. We aim to deliver a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination. Our innovative portfolio focuses on four cutting edge areas of science that we believe offer the greatest opportunities to provide meaningful solutions for patients:

  • Immuno-oncology: using the human immune system to treat cancer
  • Cell therapy: engineering human T-cells to target cancer
  • Cancer epigenetics: modulating the gene-regulatory system of the epigenome to exert anti-cancer effects
  • Synthetic lethality: targeting two mechanisms at the same time which together, but not alone, have substantial effects against cancer”

Why did GSK join Oslo Cancer Cluster?

“GSK has an increasing pipeline of new oncology assets and in the process of establishing a network within oncology. Oslo Cancer Cluster is an important part of the oncology landscape in Norway and indeed an important partner for GSK. We are looking forward to partnering with Oslo Cancer Cluster when arranging scientific meetings and dialogues, bringing investigators together for fruitful clinical research collaborations, and bridging GSK global discovery team with biotech/startup community in Norway looking for new R&D investments.”

gsk logo

Sign up to our monthly newsletter